Global Radiopharmaceuticals Industry

  • March 2015
  • -
  • Global Industry Analysts
  • -
  • 274 pages

This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 57 companies including many key and niche players such as -

Actinium Pharmaceuticals Inc.
Advanced Medical Isotope Corporation
Alliance Medical
Alseres Pharmaceuticals, Inc.
Avid Radiopharmaceuticals

Table Of Contents

Global Radiopharmaceuticals Industry



I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability And Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions And Scope Of Study I-3
A. Diagnostic Radiopharmaceuticals I-3
B. Therapeutic Radiopharmaceuticals I-4


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Quick Primer II-1
Market Drivers II-2
Growing Acceptance in Cancer Treatment II-2
Increasing Acceptance of Disease-Targeted Treatment II-2
Growing Emphasis of Accurate Diagnosis II-3
Expanding Molecular Imaging Applications II-3
Market Restraints II-3
Stringent Regulatory Guidelines II-3
Global Supply Shortages II-3
Price Sensitivity and Competition from Alternatives II-4
Lack of Dosage Standards for Pediatric Patients Limits
Radiopharmaceutical Efficacy II-4
Unfounded Fears of Radiation Exposure Hinder Growth II-5
Bottlenecks in Developing Markets II-5
Recognition of Intrinsic Cost Benefits: Critical to Market
Acceptance II-5
Market Scenario II-5
Recession: A Period of Global Decline II-5
The Road to Recovery II-6
Impact of Healthcare Budget Cuts in Developed Economies: A
Review II-6
Current and Future Analysis II-7
Diagnostic Radiopharmaceuticals: The Dominant Segment II-7
PET: A Prime Growth Driver II-8
Introduction of SPECT/CT and PET/CT Boosts Growth II-9
Select PET and SPECT Radioisotopes Used in Nuclear Medicine II-10
Select Cardiology and Oncology Radiopharmaceuticals II-10
New Therapeutic Radiopharmaceuticals to Drive Global Market II-10
Rise in Cancer Incidences and Access to Modern Therapeutics
Foster Growth II-11
World Cancer Statistics - Incidence and Mortality Data II-12
Table 1: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported in
Thousands for Asia-Oceania, Europe, North America, Latin
America and the Caribbean, and Africa (includes corresponding
Graph/Chart) II-12

Table 2: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer-Related Deaths in Thousands
for Asia-Oceania, Europe, North America, Latin America and the
Caribbean, and Africa (includes corresponding Graph/Chart) II-13

Table 3: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung and
Bronchus, Prostate, Colorectal and Liver Cancers II-13
Competition II-14

2. MARKET TRENDS and ISSUES II-15
Companies Explore New Frontiers of Therapeutic
Radiopharmaceuticals II-15
Targeted Radionuclide Therapy: Gains Ground in Cancer Treatment II-16
Battling Alzheimer's Disease - A Powerful Market Force II-16
List of FDA Approved Alzheimer's Diagnostic Imaging Agents II-18
Hypoxia Imaging Presents Opportunities for PET II-18
Rise in Investments and International Collaborations for Drug
Development II-18
Intra-operative Lymphatic Mapping (ILM): Creates New
Opportunities for Radiopharmaceuticals in Cancer Detection II-19
Cardiology: An Important Sector for Radiopharmaceuticals II-20
PET Application in Drug Development to Expand Opportunities II-21
Emergence of Radioisotope Based Personalized Therapy Bodes
Well for the Market II-22

3. RADIO ISOTOPES MO-99/TC 99 SUPPLIES - A REVIEW II-23
Reactors Producing Cobalt 60 and Molybdenum 99 II-23
Table 4: Global Projected Demand for Mo-99 in Emerging and
Mature Markets for the Years 2020 and 2030 (includes
corresponding Graph/Chart) II-24

Table 5: Worldwide Market Demand for Mo-99 by Region (2013):
Percentage Share Breakdown of Demand for Australia, Canada,
China, EU, Japan, Russia, US, and Others (includes
corresponding Graph/Chart) II-24

Table 6: Worldwide Mo-99 Production by Region (2013):
Percentage Share Breakdown of Annual Production for
Australia, Canada, EU, Russia, South Africa, and Others
(includes corresponding Graph/Chart) II-24

Table 7: Global Mo-99 Reactors by Production Capacity (2013):
Percentage Share Breakdown of Annual Production Capacity for
BR2/Belgium, HFR/ Netherlands, LVR-15/Czech Republic,
MARIA/Poland, NRU/Canada, OPAL/Australia, OSIRIS/France,
RA-3/Argentina, and SAFARI/South Africa (includes
corresponding Graph/Chart) II-25

Table 8: Global Tc-99m Processors By Production Capacity
(2013): Percentage Share Breakdown Of Annual Production
Capacity for AECL/Canada, ANSTO/Australia, CNEA/Argentina,
IRE/Belgium, Mallinckrodt/Netherlands, and NTP/South Africa
(includes corresponding Graph/Chart) II-25
Supply Shortages: A Cause of Concern II-26
Combating the Anticipated Shortage of RadioIsotopes II-26
Radiopharmacy: A Key Link in the Distribution Chain II-27
Table 9: US Radiopharmacies Market (2014): Percentage Share
Breakdown of SPECT Doses Sold by Company II-28

4. THERAPEUTIC RADIOPHARMACEUTICAL PRODUCTS UNDER DEVELOPMENT II-29
Primer II-29
Lutathera for Neuroendocrine Cancer II-29
Actimab for Leukemia and Blood Borne Cancers II-29
Lead-212 Alpha Therapy for Metastasized Abdominal Cancers II-30
Lu-177-J591 PSMA Antibody for Prostate Cancer II-30
Indium-111-Pentetreotide for Neuroendocrine Tumors II-30
Yttrium-90 Clivatuzumab for Pancreatic Cancer II-30
Phospholid Ether Tumor Targeting II-31

5. IMAGING AGENTS - AN OVERVIEW II-32
A Quick Primer II-32
Growth Drivers II-32
Market Restraints II-33
Significance of Technological Advancements II-33
X-Ray Contrast Media: Giving Way to Emerging Modalities II-33
Medical Reimbursement: A Critical Factor II-34
Market Structure II-34
Select Players by Segment II-34

6. NUCLEAR MEDICINE - AN OVERVIEW II-35
Nuclear Medicine - An Introduction II-35
Growth Drivers in a Nutshell II-35
Market Shifts to Hybrid Imaging II-35

7. PRODUCT OVERVIEW II-37
Radiopharmaceuticals: A Definition II-37
Mechanism of Action II-37
Application of Radiopharmaceuticals II-37
Radioactive Tracers for Diagnostic Imaging II-37
Therapeutics II-37
Research II-38
Sterilization II-38
Classification of Radiopharmaceuticals II-38
Diagnostic Radiopharmaceuticals II-38
Commonly Used Diagnostic Radiopharmaceutical Agents II-38
Major Isotopes and their Diagnostic Applications II-39
Advantages II-40
Classification II-40
Cardiology Diagnostics II-40
Non-cardiology Diagnostics II-40
Molecular Imaging Modalities in Radiopharmaceutical
Diagnostics II-40
Planar Imaging II-40
Positron Emission Tomography (PET) II-41
Advantages II-41
Applications of PET II-42
Commonly used Radioisotopes in PET Scans II-42
Major PET Isotopes and their Applications II-43
Single Photon Emission Computed Tomography (SPECT) II-44
Applications of SPECT II-44
Commonly used Radioisotopes in SPECT Scans II-44
Therapeutic Radiopharmaceuticals II-44
Characteristics of Therapeutic Radiopharmaceuticals II-45
Commonly used Therapeutic Agents II-45
Major Isotopes and their Therapeutic Applications II-45
Radiopharmaceuticals for Thyroid Therapy II-46
Radiopharmaceuticals for Cancer Therapy II-46
Radiopharmaceuticals for Neuroendocrine Tumors II-46
Radiopharmaceuticals for Radiosynoviorthesis Therapy II-47
Radiopharmaceuticals for Bone Pain Palliation Therapy II-47

8. PRODUCT INNOVATIONS/INTRODUCTIONS II-48
Navidea Biopharmaceuticals Launches Lymphoseek II-48
Positron Launches Advanced PosiRx Pharmacy Automation Systems II-48
BARC Launches Indigenous Radiopharmaceuticals-Powered Scans II-48
Rapidscan Pharma Solutions EU and GE Healthcare Unveil Rapiscan® II-48

9. RECENT INDUSTRY ACTIVITY II-49
Fujifilm Enters the Radiopharmaceutical Market II-49
AAA Acquires GE's Italian Radiopharmaceutical Business II-49
Triad Isotopes Awarded HealthTrust Contract II-49
Positron Enters Licensing Agreement with Russian INR II-49
Siemens to Offer PET Pharmaceutical Services in US Market II-49
Zevacor Molecular Acquires Pioneer Radiopharmacy II-49
Navidea Enters Agreement with Siemens' PETNET Solutions II-50
Positron Enters Supply Agreement with iThemba Labs II-50
Covidien Spins Off Pharmaceuticals Business II-50
Navidea Enters Agreement with Nordion II-50
Lantheus Enters into Agreement with Fujifilm II-50
Advanced Accelerator Applications Expands Radiopharmaceutical
Manufacturing Network II-50
Advanced Accelerator Applications Inks Partnership Agreement
with Uwrc Spoka Z Ograniczon Odpowiedzialno Ci II-51
Eli Lilly to Purchase Two Radiopharmaceutical Imaging Agents
from Siemens II-51
UPPI Inks Contract with Novation II-51
Dalton Inks Manufacturing Partnership with Clarity
Pharmaceuticals II-51
Lantheus Medical Imaging Extends Agreement with Nordion II-51
Lantheus Medical Imaging and Jubilant HollisterStier Enter
into Agreement II-51
NCM Reveals New Advanced PET Radiopharmaceutical Manufacturing
Center II-51
Turkey Inaugurates First Particle Accelerator II-52
SK Capital and IBA Sign Agreement to Setup IBA Molecular Imaging II-52

10. FOCUS ON SELECT PLAYERS II-53
Actinium Pharmaceuticals Inc (US) II-53
Advanced Medical Isotope Corporation (US) II-53
Alliance Medical (UK) II-53
Alseres Pharmaceuticals, Inc (US) II-54
Avid Radiopharmaceuticals (US) II-54
Bayer HealthCare Medical Care (US) II-54
Bracco Diagnostics, Inc. (US) II-55
Cardinal Health, Inc (US) II-55
GE Healthcare (UK) II-56
Ion Beam Applications S.A (Belgium) II-56
Immunomedics, Inc. (US) II-57
Jubilant Pharma (India) II-57
Lantheus Medical Imaging Inc (US) II-58
Mallinckrodt Pharmaceuticals (Ireland) II-58
Medi-Radiopharma Ltd (Hungary) II-59
Nordion, Inc. (Canada) II-59
Peregrine Pharmaceuticals, Inc. (US) II-60
PETNET Solutions Inc (US) II-60
Positron Corporation (US) II-61
Singapore Radiopharmaceuticals Pte Ltd (Singapore) II-61
Triad Isotopes, Inc. (US) II-61

11. GLOBAL MARKET PERSPECTIVE II-63
Table 10: World Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Middle East and Latin American Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2014 through 2020 (includes corresponding Graph/Chart) II-63

Table 11: World Historic Review for Radiopharmaceuticals by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Middle East and Latin American Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2007 through 2013
(includes corresponding Graph/Chart) II-64

Table 12: World 15-Year Perspective for Radiopharmaceuticals
by Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin
American Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) II-65

Table 13: World Recent Past, Current and Future Analysis for
Diagnostic Radiopharmaceuticals by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, Middle East and Latin
American Markets Independently Analyzed with Annual Sales in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) II-66

Table 14: World Historic Review for Diagnostic
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Middle East and Latin American Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2013 (includes corresponding Graph/Chart) II-67

Table 15: World 15-Year Perspective for Diagnostic
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific, Middle East and Latin American Markets for Years
2007, 2015 and 2020 (includes corresponding Graph/Chart) II-68

Table 16: World Recent Past, Current and Future Analysis for
Therapeutic Radiopharmaceuticals by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, Middle East and Latin
American Markets Independently Analyzed with Annual Sales in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) II-69

Table 17: World Historic Review for Therapeutic
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Middle East and Latin American Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2013 (includes corresponding Graph/Chart) II-70

Table 18: World 15-Year Perspective for Therapeutic
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific, Middle East and Latin American Markets for Years
2007, 2015 and 2020 (includes corresponding Graph/Chart) II-71


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Industry Structure III-1
Production Scenario III-1
Dependence on Imports III-1
Regulatory Scenario III-2
Thorny Regulations Dampen New Product Development III-2
Market Overview III-3
Expanding Diagnostic Applications Stimulate Future Growth III-3
Cardiovascular Imaging to Lead Volume Growth III-3
Table 19: The US Diagnostic Radiopharmaceutical Agents
Market (2014): Percentage Share Breakdown of Procedure
Volume by Imaging Procedure - SPECT and PET (includes
corresponding Graph/Chart) III-4

Table 20: US Market for Diagnostic Radiopharmaceuticals
Agents (2014): Percentage Share Breakdown of Value Sales
for Cardiology and Non-Cardiology Applications (includes
corresponding Graph/Chart) III-4
New Neurology Agents to Boost Growth III-4
List of FDA Approved Alzheimer's Diagnostic Imaging Agents III-5
Alzheimer's Stats III-5
Table 21: Alzheimer's Prevalence in the US: As a
Percentage of Population by Age-Group (includes
corresponding Graph/Chart) III-5

Table 22: US Market for Non-Cardiology Diagnostic
Radiopharmaceuticals Agents (2014): Percentage Share
Breakdown of Value Sales for Oncology and Non-Oncology
Applications (includes corresponding Graph/Chart) III-6
Adoption of SPECT/CT Scanners on Rise III-6
Radiopharmaceuticals in PET Imaging - Prospects III-6
Focused RandD Efforts to Fuel Therapeutic
Radiopharmaceuticals Market III-6
Market Share Statistics III-7
Table 23: US Market for Diagnostic Radiopharmaceuticals
Agents (2014): Percentage Market Share Breakdown for
Leading Players (includes corresponding Graph/Chart) III-7

Table 24: US Market for Therapeutic Radiopharmaceuticals
(2014): Percentage Share Breakdown of Value Sales by Key
Radiotherapeutics - Bone Palliation, Non-Hodgkin's
Lymphoma, Hyperthyroidism/Thyroid Cancer and Others
(includes corresponding Graph/Chart) III-7

Table 25: US Market for Therapeutic Radiopharmaceutical
Agents (2014E): Percentage Market Share Breakdown of
Leading Players (includes corresponding Graph/Chart) III-8
Rising Incidence of Cancer - A Major Growth Driver III-8
Table 26: US Cancer Incidence (2014): No. of Reported New
Cases by Gender (includes corresponding Graph/Chart) III-8

Table 27: US Incidence of Common Cancers (2014): Number of
New Cases Reported by Affected Site (includes
corresponding Graph/Chart) III-9
Overview of Medicare Reimbursements III-9
Medicare Payment Settings for Radiopharmaceuticals III-10
Table 28: Select 2015 Medicare Payment for Hospital
Outpatients and Physician Office III-10
Contrast Agents and Diagnostic Radiopharmaceuticals Bundled
As Supplies III-10
Table 29: Packaged components of SPECT Multiple Myocardial
Perfusion Procedure III-11
Product Launches III-12
Strategic Corporate Developments III-13
Select Players III-15
B.Market Analytics III-22
Table 30: US Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-22

Table 31: US Historic Review for Radiopharmaceuticals by
Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-23

Table 32: US 15-Year Perspective for Radiopharmaceuticals by
Segment - Percentage Breakdown of Value Sales for Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) III-24

2. CANADA III-25
A.Market Analysis III-25
Outlook III-25
Canadian Scientists Gear up to find Remedy for Mo-99 Supply
Shortages III-25
An Overview of Medical Imaging Market III-26
Regulatory and Legal Restrictions III-26
Select Players III-26
B.Market Analytics III-28
Table 33: Canadian Recent Past, Current and Future Analysis
for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-28

Table 34: Canadian Historic Review for Radiopharmaceuticals
by Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-29

Table 35: Canadian 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-30

3. JAPAN III-31
A.Market Analysis III-31
Outlook III-31
Healthcare in Japan III-31
Strategic Corporate Developments III-32
B.Market Analytics III-33
Table 36: Japanese Recent Past, Current and Future Analysis
for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-33

Table 37: Japanese Historic Review for Radiopharmaceuticals
by Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-34

Table 38: Japanese 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-35

4. EUROPE III-36
A.Market Analysis III-36
Outlook III-36
Competitive Scenario III-36
Key Statistics III-37
Table 39: European Radiopharmaceuticals Market (2014):
Percentage Share Breakdown of Revenues by Company (includes
corresponding Graph/Chart) III-37

Table 40: European Diagnostic Radiopharmaceuticals Market
(2014): Percentage Share Breakdown of Value Sales by
Imaging Modalities - SPECT and PET (includes corresponding
Graph/Chart) III-37
Market Trends III-37
New Applications and Products Augur Good Market Prospects III-37
B.Market Analytics III-38
Table 41: European Recent Past, Current and Future Analysis
for Radiopharmaceuticals by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-38

Table 42: European Historic Review for Radiopharmaceuticals
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2013 (includes corresponding Graph/Chart) III-39

Table 43: European 15-Year Perspective for
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-40

Table 44: European Recent Past, Current and Future Analysis
for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-41

Table 45: European Historic Review for Radiopharmaceuticals
by Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-42

Table 46: European 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-43

4a. FRANCE III-44
A.Market Analysis III-44
Outlook III-44
B.Market Analytics III-45
Table 47: French Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-45

Table 48: French Historic Review for Radiopharmaceuticals by
Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-46

Table 49: French 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-47

4b. GERMANY III-48
A.Market Analysis III-48
Outlook III-48
B.Market Analytics III-49
Table 50: German Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-49

Table 51: German Historic Review for Radiopharmaceuticals by
Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-50

Table 52: German 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-51

4c. ITALY III-52
A.Market Analysis III-52
Outlook III-52
Strategic Corporate Development III-52
B.Market Analytics III-53
Table 53: Italian Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-53

Table 54: Italian Historic Review for Radiopharmaceuticals
by Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-54

Table 55: Italian 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-55

4d. THE UNITED KINGDOM III-56
A.Market Analysis III-56
Outlook III-56
Strategic Corporate Development III-56
Select Players III-56
B.Market Analytics III-58
Table 56: UK Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-58

Table 57: UK Historic Review for Radiopharmaceuticals by
Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-59

Table 58: UK 15-Year Perspective for Radiopharmaceuticals by
Segment - Percentage Breakdown of Value Sales for Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets for Years 2007, 2015 and 2020 (includes corresponding
Graph/Chart) III-60

4e. SPAIN III-61
A.Market Analysis III-61
Outlook III-61
Strategic Corporate Development III-61
B.Market Analytics III-62
Table 59: Spanish Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-62

Table 60: Spanish Historic Review for Radiopharmaceuticals
by Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-63

Table 61: Spanish 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-64

4f. RUSSIA III-65
A.Market Analysis III-65
Outlook III-65
B.Market Analytics III-65
Table 62: Russian Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-65

Table 63: Russian Historic Review for Radiopharmaceuticals
by Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-66

Table 64: Russian 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-67

4g. REST OF EUROPE III-68
A.Market Analysis III-68
Outlook III-68
Market Overview III-68
Strategic Corporate Developments III-68
Select Players III-69
B.Market Analytics III-70
Table 65: Rest of Europe Recent Past, Current and Future
Analysis for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-70

Table 66: Rest of Europe Historic Review for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2013 (includes
corresponding Graph/Chart) III-71

Table 67: Rest of Europe 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-72

5. ASIA-PACIFIC III-73
A.Market Analysis III-73
Outlook III-73
B.Market Analytics III-74
Table 68: Asia-Pacific Recent Past, Current and Future
Analysis for Radiopharmaceuticals by Geographic Region -
China, India and Rest of Asia-Pacific Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2014 through 2020 (includes corresponding Graph/Chart) III-74

Table 69: Asia-Pacific Historic Review for
Radiopharmaceuticals by Geographic Region - China, India and
Rest of Asia-Pacific Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-75

Table 70: Asia-Pacific 15-Year Perspective for
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Value Sales for China, India and Rest of
Asia-Pacific Markets for Years 2007, 2015 and 2020 (includes
corresponding Graph/Chart) III-76

Table 71: Asia-Pacific Recent Past, Current and Future
Analysis for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-77

Table 72: Asia-Pacific Historic Review for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2013 (includes
corresponding Graph/Chart) III-78

Table 73: Asia-Pacific 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-79

5a. CHINA III-80
A.Market Analysis III-80
Outlook III-80
Medical Imaging Device Market - An Overview III-80
B.Market Analytics III-81
Table 74: Chinese Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-81

Table 75: Chinese Historic Review for Radiopharmaceuticals
by Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-82

Table 76: Chinese 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-83

5b. INDIA III-84
A.Market Analysis III-84
Outlook III-84
Product Launch III-84
Jubilant Pharma - A Key Player III-84
B.Market Analytics III-85
Table 77: Indian Recent Past, Current and Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-85

Table 78: Indian Historic Review for Radiopharmaceuticals by
Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-86

Table 79: Indian 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-87

5c. REST OF ASIA-PACIFIC III-88
A.Market Analysis III-88
Outlook III-88
Strategic Corporate Development III-88
Singapore Radiopharmaceuticals Pte Ltd. - A Key Player III-88
B.Market Analytics III-89
Table 80: Rest of Asia-Pacific Recent Past, Current and Future
Analysis for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-89

Table 81: Rest of Asia-Pacific Historic Review for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2013 (includes
corresponding Graph/Chart) III-90

Table 82: Rest of Asia-Pacific 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-91

6. MIDDLE EAST III-92
A.Market Analysis III-92
Outlook III-92
B.Market Analytics III-92
Table 83: Middle East Recent Past, Current and Future Analysis
for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-92

Table 84: Middle East Historic Review for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2013 (includes
corresponding Graph/Chart) III-93

Table 85: Middle East 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-94

7. LATIN AMERICA III-95
A.Market Analysis III-95
Outlook III-95
B.Market Analytics III-96
Table 86: Latin American Recent Past, Current and Future
Analysis for Radiopharmaceuticals by Region - Brazil and
Rest of Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2014 through
2020 (includes corresponding Graph/Chart) III-96

Table 87: Latin American Historic Review for
Radiopharmaceuticals by Region - Brazil and Rest of Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2013 (includes
corresponding Graph/Chart) III-97

Table 88: Latin American 15-Year Perspective for
Radiopharmaceuticals by Region - Percentage Breakdown of
Value Sales for Brazil and Rest of Latin America Markets for
Years 2007, 2015 and 2020 (includes corresponding Graph/Chart) III-98

Table 89: Latin American Recent Past, Current and Future
Analysis for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-99

Table 90: Latin American Historic Review for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2013 (includes
corresponding Graph/Chart) III-100

Table 91: Latin American 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-101

7a. BRAZIL III-102
A.Market Analysis III-102
Outlook III-102
B.Market Analytics III-102
Table 92: Brazilian Recent Past, Current and Future Analysis
for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2014 through 2020 (includes
corresponding Graph/Chart) III-102

Table 93: Brazilian Historic Review for Radiopharmaceuticals
by Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2013 (includes corresponding Graph/Chart) III-103

Table 94: Brazilian 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-104

7b. REST OF LATIN AMERICA III-105
A.Market Analysis III-105
Outlook III-105
B.Market Analytics III-105
Table 95: Rest of Latin America Recent Past, Current and
Future Analysis for Radiopharmaceuticals by Segment -
Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2014 through
2020 (includes corresponding Graph/Chart) III-105

Table 96: Rest of Latin America Historic Review for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2013 (includes
corresponding Graph/Chart) III-106

Table 97: Rest of Latin America 15-Year Perspective for
Radiopharmaceuticals by Segment - Percentage Breakdown of
Value Sales for Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Markets for Years 2007,
2015 and 2020 (includes corresponding Graph/Chart) III-107


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 57 (including Divisions/Subsidiaries - 64)

The United States (28)
Canada (2)
Japan (1)
Europe (22)
- France (2)
- Germany (3)
- The United Kingdom (3)
- Italy (2)
- Spain (1)
- Rest of Europe (11)
Asia-Pacific (Excluding Japan) (9)
Latin America (1)
Africa (1)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

The 2016-2021 World Outlook for Diagnostic Radiopharmaceuticals

The 2016-2021 World Outlook for Diagnostic Radiopharmaceuticals

  • $ 995
  • Industry report
  • April 2015
  • by ICON Group

This econometric study covers the world outlook for diagnostic radiopharmaceuticals across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry ...

MediPoint: Nuclear Imaging - US Analysis and Market Forecasts

MediPoint: Nuclear Imaging - US Analysis and Market Forecasts

  • $ 4 450
  • Industry report
  • December 2014
  • by Global Data

MediPoint: Nuclear Imaging - US Analysis and Market Forecasts Summary This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, ...

MediPoint: Nuclear Imaging - APAC Analysis and Market Forecasts

MediPoint: Nuclear Imaging - APAC Analysis and Market Forecasts

  • $ 4 450
  • Industry report
  • December 2014
  • by Global Data

MediPoint: Nuclear Imaging - APAC Analysis and Market Forecasts Summary This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.